Methoxyflavone inhibitors of cytochrome P450

被引:8
|
作者
McKendall, Michael [1 ]
Smith, Tasha [1 ]
Anh, Kien [1 ]
Ellis, Jamie [1 ]
McGee, Terri [1 ]
Foroozesh, Maryam [1 ]
Zhu, Naijue [1 ]
Stevens, Cheryl L. Klein [1 ]
机构
[1] Xavier Univ, Dept Chem, New Orleans, LA 70125 USA
关键词
flavone; P450; inhibitors; X-ray crystal structures;
D O I
10.1007/s10870-007-9310-x
中图分类号
O7 [晶体学];
学科分类号
0702 ; 070205 ; 0703 ; 080501 ;
摘要
Cytochrome P450 enzymes are a superfamily of enzymes involved in the metabolism of endogenous compounds as well as xenobiotics. Due to the large number of reactions catalyzed by these enzymes and their importance in drug metabolism and carcinogenesis, they have been the focus of many studies over the years. Based on the knowledge that flavones are natural substrates of certain P450 enzymes (such as P450 1A2) involved in carcinogenesis, we have synthesized and studied a number of flavonoids as potential inhibitors of these enzymes. These compounds are structurally very similar to the natural flavone substrates of these enzymes but have methoxy substituents at various positions. Here we are reporting the synthesis, structural analysis, X-ray crystal structures, and preliminary inhibition studies of four methoxyflavones from this series. Crystallographic data: 2'-methoxyflavone, P-1, a = 7.2994(8) angstrom, b = 8.3322(7) angstrom, c = 10.8240(10) angstrom, alpha = 97.905(8)degrees, beta = 92.779(10)degrees, gamma = 111.105(8)degrees, V = 604.9(1) angstrom(3); 3'-methoxyflavone, P2(1)/n, a = 15.1313(16) angstrom, b = 3.9699(4) angstrom, c = 19.9454(16) angstrom, beta = 91.673(8)degrees, V = 1197.6(2) angstrom(3); 4'-methoxyflavone, P2(1)/n, a = 16.451(12) angstrom, b = 3.881(1) angstrom, c = 19.529(16) angstrom, beta = 106.65(1)degrees, V = 1195.1(4) angstrom(3); 3',4'-dimethoxyflavone, C2/c, a = 30.819(5) angstrom, b = 4.0857(7) angstrom, c = 26.100(3) angstrom, beta = 124.21(1)degrees, V = 2717.6(7) angstrom(3).
引用
收藏
页码:231 / 237
页数:7
相关论文
共 50 条
  • [41] Blueing with cytochrome P450
    Brennan, M
    CHEMICAL & ENGINEERING NEWS, 2001, 79 (02) : 30 - 30
  • [42] QSAR of cytochrome P450
    Hansch, C
    Mekapati, SB
    Kurup, A
    Verma, RP
    DRUG METABOLISM REVIEWS, 2004, 36 (01) : 105 - 156
  • [43] Cytochrome P450 and Steatosis
    Jose Gomez-Lechon, Maria
    Jover, Ramiro
    Teresa Donato, Maria
    CURRENT DRUG METABOLISM, 2009, 10 (07) : 692 - 699
  • [44] Introduction: Cytochrome P450
    Masters, BSS
    FASEB JOURNAL, 1996, 10 (02): : 205 - 205
  • [45] Cytochrome P450 - Preface
    Lu, AYH
    CURRENT DRUG METABOLISM, 2001, 2 (02) : U4 - U4
  • [46] Cytochrome P450 engineering
    Pompon, Denis
    Truan, Gilles
    Urban, Philippe
    BIOFUTUR, 2008, (288) : 34 - 38
  • [47] Preface: Cytochrome P450
    Plettner, Erika
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2018, 1866 (01): : 1 - 1
  • [48] Interaction of cytochrome P450 3A inhibitors with P-glycoprotein
    Yasuda, K
    Lan, LB
    Sanglard, D
    Furuya, K
    Schuetz, JD
    Schuetz, EG
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (01): : 323 - 332
  • [49] Structure of Cytochrome P450 Reductase in an Open Conformation Capable of Reducing Cytochrome P450
    Waskell, Lucy
    Kim, Jung-Ja P.
    Hamdane, Djemel
    Xia, Chuanwu
    Im, Sang-Choul
    Zhang, Haoming
    FASEB JOURNAL, 2009, 23
  • [50] A Minimal Functional Complex of Cytochrome P450 and FBD of Cytochrome P450 Reductase in Nanodiscs
    Prade, Elke
    Mahajan, Mukesh
    Im, Sang-Choul
    Zhang, Meng
    Gentry, Katherine A.
    Anantharamaiah, G. M.
    Waskell, Lucy
    Ramamoorthy, Ayyalusamy
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2018, 57 (28) : 8458 - 8462